Background: Digital weight loss services (DWLSs) that use Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated potential in contributing to a shift in global obesity rates. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.